Press Releases

Initiator Pharma A/S, a clinical-stage biotech company, today announced that the World Health Organization (WHO) has selected the International Nonproprietary Name (INN) pudafensine as the official generic name for the company’s patented candidate drug IP2015, which is in clinical development in erectile dysfunction and neuropathic pain.

Initiator Pharma A/S, a clinical-stage biotech company, today announced that it has completed dosing all 24 patients for its Phase 2a clinical trial with IP2018. Draft results are expected end of Q2 2023, as previously communicated.

Initiator Pharma A/S, a clinical-stage pharma company, announced today its decision not to exercise the exclusive option agreement for a Phase II/III ready pharmaceutical asset. With this decision the company reiterates previous statement that its current cash position will be sufficient to fund all planned and committed activities through 2024.

Initiator Pharma A/S, a clinical-stage pharma company, announced today that it will initiate a Phase I pharmacokinetic study in healthy subects evaluating new oral solid dosage forms enabling a bridging between previous data sets into new future clinical studies for IP2015.

Initiator Pharma A/S, a clinical-stage pharma company, announced today an update on its ongoing and planned clinical studies.

Initiator Pharma A/S, a clinical-stage pharma company, announced today that the final dataset and study- report analysis have been obtained in the IPTN2021 program. The IPTN2021 program is a clinical Phase I study in healthy subjects dosed with the drug IP2015 and challenged with a pain-inducing ingredient (capsaicin). The final analysis confirms the statistically significant effects on pain measures that were observed in the analysis of the first data read-out from the study presented in May 2022.

Initiator Pharma A/S (“Initiator” or the “Company”) has today finalized the share buyback that was announced on 22 June 2022

The Board of Directors of Initiator Pharma A/S (“Initiator” or the “Company”) has today resolved to prolong the duration of the share buyback until 26 July 2022

Initiator Pharma A/S, a clinical-stage pharma company, announced today that all planned subjects have had the last visit in Clinical part in the IPTN2021 program clinical Phase I study in healthy subjects challenged with the pain-inducing ingredient (capsaicin).

Initiator Pharma A/S, a clinical-stage pharma company, announced today that it has signed an exclusive option agreement for a Phase 2/3 ready drug asset for an undisclosed pain indication.